跳至主要内容
临床试验/NCT01553617
NCT01553617已完成4 期

Efficacy and Safety of Perioperative Infusion of 6 % Hydroxyethyl Starch 130/0.4 in an Isotonic Electrolyte Solution (VolulyteTM) vs. 5% HSA as Volume Replacement Therapy During Cardiac Surgery for Adult Patients

Fresenius Kabi5 个研究点 分布在 1 个国家目标入组 133 人开始时间: 2012年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
133
试验地点
5
主要终点
Calculated red blood cell loss

研究概览

简要总结

The study will compare the efficacy and safety of VolulyteTM and human albumin in elective open-heart surgery in adult patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • male or female adult patients
  • undergoing primary elective cardiac surgery applying extracorporeal circulation
  • signed written informed consent

排除标准

  • known contraindication against scheduled medication
  • pre-operative acute normovolaemic haemodilution or preoperative autologous blood donation
  • planned systemic hypothermia (body temperature < 30°C)
  • expected time on ECC ≥ 2 hours

研究组 & 干预措施

Volulyte

Experimental

6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)

干预措施: 6% hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM) (Drug)

Human serum albumin

Active Comparator

Human serum albumin (HSA 50g/L)

干预措施: Human serum albumin (Drug)

结局指标

主要结局

Calculated red blood cell loss

时间窗: up to 3rd postoperative day

次要结局

  • Haemodynamics(up to 3rd postoperative day)
  • Fluid input/output(up to 3rd postoperative day)
  • Use of vasoactive and inotropic drugs(up to 3rd postoperative day)
  • Laboratory parameters(up to 3rd postoperative day)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (5)

Loading locations...

相似试验